CAMBRIDGE, UK I April 2013 I Antitope Ltd., UK (“Antitope”) today announced a Research Agreement with Research Corporation Technologies, Inc., USA (“RCT”) to re-engineer a toxic protein warhead for the next generation of antibody-drug-conjugates (ADCs) using its proprietary Composite Protein™ technology. The resulting “deimmunised” protein is expected to have a range of therapeutic applications especially in treatment of cancers. Under the Agreement, Antitope will be eligible for research fees and subsequent milestone and royalty payments.
“We are delighted to have been chosen by RCT in this exciting collaboration to produce a novel therapeutic protein with a broad range of clinical applications” said Dr. Matthew Baker, Chief Scientific Officer and co-founder of Antitope Limited. “This collaboration, using Antitope’s expertise in protein engineering and immunogenicity technologies, will assist RCT in progressing the new molecule to the clinical stage.”
“We are pleased to be working with Antitope to deimmunise our protein warhead using their proven technology platform. RCT plans to partner the new warhead with companies interested in developing novel ADC products to treat cancer and other diseases”, said Kurt R. Gehlsen, Chief Scientific Officer of RCT.
About Antitope
Antitope Ltd. is a privately-held Cambridge, UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. The proprietary Composite Human Antibody™ and Composite Protein™ technologies result in the generation of fully humanised antibodies and therapeutic proteins devoid of T cell epitopes. Antitope’s proprietary Composite CHO™ technology results in the generation of high yielding manufacturing cell lines suitable for direct transfer to GMP manufacture. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.
About Research Corporation Technologies
RCT is a Tucson, Arizona-based technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies. RCT focuses on technology investments with origins from universities and research institutions worldwide. RCT’s technology portfolio includes platforms that support the discovery, development and manufacturing of therapeutics. Current platform technologies include Pichia and E.coli protein expression systems and novel protein binding scaffolds. To learn more about RCT and our business, see www.rctech.com.
SOURCE: Antitope
Post Views: 225
CAMBRIDGE, UK I April 2013 I Antitope Ltd., UK (“Antitope”) today announced a Research Agreement with Research Corporation Technologies, Inc., USA (“RCT”) to re-engineer a toxic protein warhead for the next generation of antibody-drug-conjugates (ADCs) using its proprietary Composite Protein™ technology. The resulting “deimmunised” protein is expected to have a range of therapeutic applications especially in treatment of cancers. Under the Agreement, Antitope will be eligible for research fees and subsequent milestone and royalty payments.
“We are delighted to have been chosen by RCT in this exciting collaboration to produce a novel therapeutic protein with a broad range of clinical applications” said Dr. Matthew Baker, Chief Scientific Officer and co-founder of Antitope Limited. “This collaboration, using Antitope’s expertise in protein engineering and immunogenicity technologies, will assist RCT in progressing the new molecule to the clinical stage.”
“We are pleased to be working with Antitope to deimmunise our protein warhead using their proven technology platform. RCT plans to partner the new warhead with companies interested in developing novel ADC products to treat cancer and other diseases”, said Kurt R. Gehlsen, Chief Scientific Officer of RCT.
About Antitope
Antitope Ltd. is a privately-held Cambridge, UK-based biotechnology company specialising in immunogenicity testing and the engineering of therapeutic antibodies/proteins with reduced immunogenicity. Antitope’s proprietary EpiScreen™ technology enables preclinical analysis of the potential for immunogenicity of therapeutic antibodies and proteins. The proprietary Composite Human Antibody™ and Composite Protein™ technologies result in the generation of fully humanised antibodies and therapeutic proteins devoid of T cell epitopes. Antitope’s proprietary Composite CHO™ technology results in the generation of high yielding manufacturing cell lines suitable for direct transfer to GMP manufacture. Antitope has established multiple commercial relationships with leading biotechnology and pharmaceutical companies worldwide.
About Research Corporation Technologies
RCT is a Tucson, Arizona-based technology investment and management company that provides early-stage funding and development for promising biomedical companies and technologies. RCT focuses on technology investments with origins from universities and research institutions worldwide. RCT’s technology portfolio includes platforms that support the discovery, development and manufacturing of therapeutics. Current platform technologies include Pichia and E.coli protein expression systems and novel protein binding scaffolds. To learn more about RCT and our business, see www.rctech.com.
SOURCE: Antitope
Post Views: 225
